CD30 antigen in non-Hodgkin's lymphoma

Area of Science:

• Immunohistochemistry
• Oncology
• Pathology

Background:

• The CD30 antigen is a marker found on certain lymphoid cells.
• Its expression patterns in various lymphoid neoplasms and reactive conditions require detailed investigation for diagnostic clarity.

Purpose of the Study:

• To investigate the expression of CD30 antigen in different types of lymphoid neoplasms and reactive lesions.
• To correlate CD30 expression with specific lymphoma subtypes, clinical stages, and patient prognosis.

Main Methods:

• Immunohistochemical analysis using the monoclonal antibody BerH2.
• Examination of tissue samples from patients with Hodgkin's disease, anaplastic large cell lymphomas, T-cell and B-cell lymphomas, malignant histiocytosis, plasmacytomas, and reactive lesions.

Main Results:

• CD30 antigen was highly expressed in Hodgkin's disease and anaplastic large cell lymphomas.
• Expression was significantly more frequent in T-cell lymphomas than B-cell lymphomas (P < 0.05).
• CD30 expression was less frequent in stage I disease and showed variable positivity in reactive cells.

Conclusions:

• CD30 antigen expression is a valuable diagnostic marker for Hodgkin's disease and anaplastic large cell lymphomas.
• Its presence in T-cell lymphomas may indicate a more favorable prognosis in high-grade cases.
• Careful interpretation of CD30-positive cells is crucial for accurate histopathologic diagnosis of lymphoid neoplasms.